RISE Life Science Gears Up to Build Long-term Value


Ryan Allway

March 15th, 2018

Exclusive, News, Top News


RISE Life Science Corp. (CSE: RLSC), formerly Luminor Technologies Inc., recently partnered with Constance Therapeutics, changed its name, and changed its ticker symbol to reflect its new focus on introducing cannabis-based wellbeing products starting in California this year. The new focus aims to capitalize on two large and growing markets: Legal cannabis and sexual health and wellness, which form a combined $10+ billion market opportunity.

Let’s take a look at the company’s new focus and its new additions to the Board of Directors that could help ensure it’s long-term success.

Focus on Wellness Products

RISE Life Science is focused on developing botanical formulations to support adult sexual health and wellness. In partnership with Constance Therapeutics, the company will build and manage a retail sales and distribution channel, as well as deploy a direct sales team to sign top-tier dispensaries, while CT will leverage it new R&D and manufacturing facilities in California to mass produce the new products under license to RISE to sell through these channels. RISE aims to have 240 dispensaries signed up to sell its products by the end of the year.

“Constance Therapeutics represents an evidence-based process,” said RISE Life Science CEO Anton Mattadeen. “Her company has been focused on producing scientifically derived cannabis products for the past 10 years — everything that goes through her process is completely vetted. The botanicals that are used are not haphazard; they’ve actually been tested for efficacy and for their ability to work well with cannabis components. Constance brings a solid scientific base to the formulations that we are creating — she’s making those products better and it places us in the position where we can have constant improvement as we go through the process.”

These products are targeting a large and growing end market in the most populous U.S. state. California’s cannabis revenue is projected to reach $3.7 billion by the end of this year and rise to $5.1 billion in 2019, according to BDS Analytics. These revenue are driven by a maturing market with more dispensaries and cultivation operations coming online every day. At the same time, Grand View Research sees the U.S. sexual wellness market as expanding to $8.8 billion by 2025, thanks to an aging population and new and innovative products.

Adding New Expertise

RISE Life Science appointed three new members to its Board of Directors earlier this month, including Chris Dollard, Constance Finley, and Michael Campbell, to help expedite its entry into the new business and ensure its long-term success. These new board members will add tremendous expertise to help guide the company in its new direction.

The new board members include:

  • Chris Dollard has served as RISE Life Science’s Chief Operating Officer since its inception in 2015 and brings a wealth of knowledge and experience from his work with operational planning and facility design in early cannabis licensed producer applications.
  • Constance Finley founded Constance Therapeutics after her own experience with autoimmune disease and the negative side-effects of pharmaceuticals led to her successfully investigate cannabis as an alternative treatment. Since then, the company has rapidly grown in both scale and reputation to focus on creating standardized, whole plant cannabis extracts to capitalize on the entourage effect.
  • Michael Campbell is the General Counsel and Corporate Secretary for Intellipharmaceuticals International Inc., which specializes in the research and development of novel and generic controlled and targeted release oral solid dosage drugs.

In addition to the new board members, the company announced the appointment of Robert Lelovic, CPA, CA as Chief Financial Officer. After graduating from York University in 1998, Mr. Lelovic has been a chartered accountant since 2001 with extensive experience working with public company reporting, corporate governance, and compliance. He will replace Chris Carmichael who previously filled the role since the company’s inception.

Looking Ahead

RISE Life Science Corp. (CSE: RLSC) represents a compelling investment opportunity targeting the rapidly growing cannabis and sexual health and wellness markets. With its Constance Therapeutics partnership, the company is uniquely positioned to scale into California’s growing market with a focus on sexual health and wellness. The addition of experienced board members and a new CFO could further ensure that the company successfully builds shareholder value over the long-term.

For more information, visit the company’s website at www.riselifescience.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please see our disclaimer below and follow the link to view our full disclosure outlining compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading